Final Research Plan: Pregnant Women
Human Immunodeficiency Virus (HIV) Infection: Screening
June 15, 2017
Recommendations made by the USPSTF are independent of the U.S. government. They should not be construed as an official position of the Agency for Healthcare Research and Quality or the U.S. Department of Health and Human Services.
The final Research Plan is used to guide a systematic review of the evidence by researchers at an Evidence-based Practice Center. The resulting Evidence Review will form the basis of the USPSTF Recommendation Statement on this topic.
The draft Research Plan was available for comment from February 23 to March 22, 2017.
* Harms of screening include false-positive results, anxiety and effects of labeling, and partner discord, abuse, or violence.
† Harms of treatment include adverse maternal and infant outcomes associated with use of antiretroviral therapy.
Abbreviation: HIV=human immunodeficiency virus.
- What are the benefits of screening for HIV infection in pregnant women on risk of mother-to-child transmission of HIV infection?
- What is the yield (number of new diagnoses per number of tests performed) of repeat HIV screening at different intervals in pregnant women, and how does the yield of screening vary in different risk groups?
- What are the harms of screening for HIV infection in pregnant women?
- What is the effectiveness of currently recommended antiretroviral therapy regimens for reducing mother-to-child transmission of HIV infection?
- What are the harms of currently recommended antiretroviral therapy regimens given during pregnancy to the mother and infant?
The Research Approach identifies the study characteristics and criteria that the Evidence-based Practice Center will use to search for publications and to determine whether identified studies should be included or excluded from the Evidence Review. Criteria are overarching as well as specific to each of the key questions (KQs).
||Studies of screening conducted in low and middle-income countries, unless fair- or good-quality studies in the United States are not available.|
|Populations||KQs 1–3: Asymptomatic pregnant women
KQ 4: Pregnant women living with HIV and their infants
KQ 5: Women who received antiretroviral therapy regimens while pregnant; neonates, infants, and children who were exposed to antiretroviral therapy in utero
|KQs 1–3: Women who have known HIV infection, are on dialysis, are posttransplant, or have occupational exposure (due to risk of needle stick or other parenteral exposure); women with known infection with hepatitis C virus, hepatitis B virus, or tuberculosis
KQs 4, 5: Women who are already or were previously taking antiretroviral therapy prior to pregnancy; women with acute HIV infection; studies limiting enrollment to persons with hepatitis C virus, hepatitis B virus, or tuberculosis coinfection
|Interventions||KQs 1–3: Rapid or standard HIV testing
KQs 4, 5: Currently recommended antiretroviral therapy regimens
|KQs 4, 5: Women who discontinue antiretroviral therapy during pregnancy; women who experience treatment interruption|
|Comparisons||KQs 1, 3: HIV screening vs. no screening
KQ 2: Repeat HIV screening during pregnancy vs. one-time screening; screening at one interval vs. another
KQs 4, 5: Currently recommended antiretroviral therapy regimens vs. placebo, older antiretroviral therapy regimens, or one another
|Outcomes||KQ 1: Mother-to-child HIV transmission rates
KQ 2: Number of positive tests per number of screening tests performed
KQ 3: False-positive results, anxiety and effects of labeling, and partner discord, abuse, or violence
KQ 4: Mother-to-child HIV transmission rates
KQ 5: Harmful effects on pregnancy outcomes, neonatal outcomes, or exposed children; long-term cardiovascular and metabolic maternal outcomes
|KQs 1, 5: Pharmacokinetic outcomes|
|Study designs||KQs 1–4: Randomized, controlled trials and controlled observational studies
KQ 5: Randomized trials and controlled observational studies
|KQs 1–4: Modeling studies|
|Timing||KQ 5: Any timing|
The draft Research Plan was posted for public comment on the USPSTF Web site from February 23, 2017 to March 22, 2017. In response to comments, the USPSTF revised the analytic framework to differentiate the harms of screening from the harms of treatment, clarify the diagnostic staging step, and clarify that the evidence review will focus on the benefits and harms of treatment with antiretroviral therapy. The USPSTF also clarified that the study settings will include prenatal, antenatal, and family planning clinics; replaced the term "newer antiretroviral therapy" with "currently approved antiretroviral therapy"; and revised the criteria for study populations to exclude persons with hepatitis C virus, hepatitis B virus, or tuberculosis coinfection. The USPSTF decided not to add benefits of initiating long-term antiretroviral therapy in women as a result of prenatal screening as an outcome because the evidence review will focus on the effects of screening on mother-to-child transmission. The general benefits of long-term antiretroviral therapy will be addressed in a separate evidence review on screening for HIV infection in nonpregnant persons.